---
title: 'Peripheral neuropathy: from guidelines to clinical practise'
date: '2025-01-27'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39869027/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20250127170523&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'PURPOSE OF REVIEW: Chemotherapy-induced peripheral neuropathy (CIPN)
  is a substantial adverse effect of anticancer therapy. No effective preventive strategies
  are established in clinical routine, although some forms of cryotherapy or compression
  therapy seem to be promising. CIPN is difficult to grade objectively and has mostly
  relied on a clinician- or patient-based rating that is subjective and not easily
  ...'
disable_comments: true
---
PURPOSE OF REVIEW: Chemotherapy-induced peripheral neuropathy (CIPN) is a substantial adverse effect of anticancer therapy. No effective preventive strategies are established in clinical routine, although some forms of cryotherapy or compression therapy seem to be promising. CIPN is difficult to grade objectively and has mostly relied on a clinician- or patient-based rating that is subjective and not easily ...